Wie hoch ist der Preis für AIkido Pharma Inc. (AIKI)

Preis für AIkido Pharma Inc. (AIKI) ist $3.56

Wie hoch ist die Marktkapitalisierung für AIkido Pharma Inc. (AIKI)

Marktkapitalisierung für AIkido Pharma Inc. (AIKI) ist $18.70M

AIkido Pharma Inc. (AIKI) EPS

AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.

Jahr	EPS	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

EPS

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	EPS	EPS-Differenz	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$2.98	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Unternehmen

EPS

EPS-Differenz

Land